Immunic MS RnD Day New York City Recording

Описание: Management of Immunic, including Daniel Vitt, Ph.D., Chief Executive Officer; Jason Tardio, M.B.A., Chief Operating Officer and President; Andreas Muehler, M.D., M.B.A., Chief Medical Officer; and Hella Kohlhof, Ph.D., Chief Scientific Officer, was joined by two of the MS industry’s renowned experts to discuss the MS landscape as well as Immunic’s orally available lead-asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838) and its potential to become the treatment of choice for both relapsing and progressive MS patients.

The MS R&D Day took place on Tuesday, September 10, 2024 in-person in New York City.

0:00 Welcome and Introductions
8:52 The Commercial Opportunity
29:48 Relevance of Nurr1 as an Emerging Neurodegenerative Target
34:01 Featured Expert: Francesca Montarolo, PhD
57:57 Vidofludimus Calcium: First-in-Class Nurr1 Activator
1:16:47 Ongoing Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing MS
1:25:53 Relevance of Neuroprotection and Preventing Disability Worsening for MS Patients
1:31:30 Featured Expert: Amit Bar-Or, MD, FRCPC
2:07:29 Ongoing Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive MS
2:16:48 Upcoming Milestones for Vidofludimus Calcium in MS
2:20:00 Q&A Session